Author

admin

Browsing

President Donald Trump’s choice to lead the Food and Drug Administration (FDA), Johns Hopkins School of Medicine professor Dr. Marty Makary, cleared a key vote in the Senate on Tuesday, the last such test before his final confirmation vote. 

The Senate voted 56-44 to invoke cloture on the nomination. 

A final vote to confirm the FDA nominee is slated for after 8 p.m. Tuesday. 

Makary, a former Fox News medical contributor, went before the Senate Committee on Health, Education, Labor and Pensions (HELP) earlier this month and answered various questions on vaccines, chronic illness, food safety and abortion. 

During his hearing, the nominee faced scrutiny over an FDA vaccine meeting that was reportedly postponed at the last minute. 

‘So if you are confirmed, will you commit to immediately reschedule that FDA Vaccine Advisory Committee meeting to get the expert views?’ Sen. Patty Murray, D-Wash., asked Makary at the time. 

He responded that he ‘would reevaluate which topics deserve a convening of the advisory committee members on [Vaccines and Related Biological Products Advisory Committee] and which may not require a convening.’ 

When this response wasn’t good enough for Murray, Makary flipped the question, telling her to confront the Biden administration. ‘Well, you can ask the Biden administration that chose not to convene the committee meeting for the COVID vaccine booster,’ he said. 

He was referring to the Biden administration in 2021 pushing through FDA approval for a COVID-19 booster for everyone over the age of 18. 

‘The FDA did not hold a meeting of the Vaccines and Related Biological Products Advisory Committee on these actions,’ read a press release at the time, ‘as the agency previously convened the committee for extensive discussions regarding the use of booster doses of COVID-19 vaccines and, after review of both Pfizer’s and Moderna’s EUA requests, the FDA concluded that the requests do not raise questions that would benefit from additional discussion by committee members.’

Committee member Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, criticized the administration’s move, saying, ‘We’re being asked to approve this as a three-dose vaccine for people 16 years of age and older, without any clear evidence if the third dose for a younger person when compared to an elderly person is of value.’

Makary has long been a critic of the administration he is poised to lead. He wrote an opinion piece in 2021, calling for ‘fresh leadership at the FDA to change the culture at the agency and promote scientific advancement, not hinder it.’

‘We now have a generational opportunity in American healthcare,’ he said at his hearing. ‘President Trump and Secretary Kennedy’s focus on healthy foods has galvanized a grassroots movement in America. Childhood obesity is not a willpower problem, and the rise of early-onset Alzheimer’s is not a genetic cause. We should be, and we will, be addressing food as it impacts our health.’

This post appeared first on FOX NEWS

The full Senate voted Tuesday evening to confirm President Donald Trump’s pick to lead the National Institutes of Health (NIH), Dr. Jay Bhattacharya.

The party-line vote followed approval from the Senate Committee on Health, Education, Labor and Pensions, which also voted along party lines to advance Bhattacharya, leading to today’s full Senate vote.  

A physician, Stanford professor of medicine and senior fellow at the university’s Institute for Economic Policy Research, Bhattacharya was a leading voice during the COVID-19 pandemic against lockdown measures and vaccine mandates. 

He was one of the co-authors of the Great Barrington Declaration, a document published in October 2020 by a group of scientists advocating against widespread COVID lockdowns and promoting the efficacy of natural immunity for low-risk individuals as opposed to vaccination.

Bhattacharya was probed by the Senate HELP Committee earlier this month over various issues related to his potential role as NIH director. However, for much of the hearing, he was forced to defend the president’s decision to cut certain research funds at NIH, including a 15% cap on indirect research costs, also known as facilities and administrative costs, dispersed by the NIH.

Bhattacharya would not explicitly say he disagreed with the cuts, or that, if confirmed, he would step in to stop them. Rather, he said he would ‘follow the law,’ while also investigating the effect of the cuts and ensuring every NIH researcher doing work that advances the health outcomes of Americans has the resources necessary.

‘I think transparency regarding indirect costs is absolutely worthwhile. It’s something that universities can fix by working together to make sure that where that money goes is made clear,’ Bhattacharya said of the indirect costs going to universities, hospitals and research clinics from the NIH. 

In addition to addressing questions about the Trump cuts, Bhattacharya also laid out what he called a new, decentralized vision for future research at NIH that he said will be aimed at embracing dissenting ideas and transparency, while focusing on research topics that have the best chance at directly benefiting health outcomes of Americans. Bhattacharya added that he wants to rid the agency’s research portfolio of other ‘frivolous’ efforts that he says do little to directly benefit health outcomes.

‘I think fundamentally what matters is do scientists have an idea that advances the scientific field they’re in?’ Bhattacharya said last week during his confirmation testimony. ‘Do they have an idea that ends up addressing the health needs of Americans?’

Prior to his confirmation, Bhattacharya, alongside several other scientists, including Trump’s pick to head the Food and Drug Administration, Dr. Marty Makary, launched a new research journal focused on spurring scientific discourse and combating ‘gatekeeping’ in the medical research community. The journal, the Journal of the Academy of Public Health (JAPH), aims to spur scientific discourse by publishing peer reviews of prominent studies from other journals that do not make their peer reviews publicly available.

This post appeared first on FOX NEWS

President Donald Trump’s choice to lead the Food and Drug Administration (FDA), Johns Hopkins School of Medicine professor Dr. Marty Makary, was confirmed in the Senate on Tuesday.

His confirmation was cemented just hours after he cleared one last procedural test vote earlier in the evening. 

The Senate voted 56-44 to invoke cloture on the nomination prior to his final confirmation.

Makary, a former Fox News medical contributor, went before the Senate Committee on Health, Education, Labor and Pensions (HELP) earlier this month and answered various questions on vaccines, chronic illness, food safety and abortion. 

During his hearing, the nominee faced scrutiny over an FDA vaccine meeting that was reportedly postponed at the last minute. 

‘So if you are confirmed, will you commit to immediately reschedule that FDA Vaccine Advisory Committee meeting to get the expert views?’ Sen. Patty Murray, D-Wash., asked Makary at the time. 

He responded that he ‘would reevaluate which topics deserve a convening of the advisory committee members on [Vaccines and Related Biological Products Advisory Committee] and which may not require a convening.’ 

When this response wasn’t good enough for Murray, Makary flipped the question, telling her to confront the Biden administration. ‘Well, you can ask the Biden administration that chose not to convene the committee meeting for the COVID vaccine booster,’ he said. 

He was referring to the Biden administration in 2021 pushing through FDA approval for a COVID-19 booster for everyone over the age of 18. 

‘The FDA did not hold a meeting of the Vaccines and Related Biological Products Advisory Committee on these actions,’ read a press release at the time, ‘as the agency previously convened the committee for extensive discussions regarding the use of booster doses of COVID-19 vaccines and, after review of both Pfizer’s and Moderna’s EUA requests, the FDA concluded that the requests do not raise questions that would benefit from additional discussion by committee members.’

Committee member Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, criticized the administration’s move, saying, ‘We’re being asked to approve this as a three-dose vaccine for people 16 years of age and older, without any clear evidence if the third dose for a younger person when compared to an elderly person is of value.’

Makary has long been a critic of the administration he will now lead. He wrote an opinion piece in 2021, calling for ‘fresh leadership at the FDA to change the culture at the agency and promote scientific advancement, not hinder it.’

‘We now have a generational opportunity in American healthcare,’ he said at his hearing. ‘President Trump and Secretary Kennedy’s focus on healthy foods has galvanized a grassroots movement in America. Childhood obesity is not a willpower problem, and the rise of early-onset Alzheimer’s is not a genetic cause. We should be, and we will, be addressing food as it impacts our health.’

This post appeared first on FOX NEWS

Sen. Josh Hawley, R-Mo., has lingering questions about President Donald Trump’s Centers for Medicare & Medicaid Services (CMS) nominee, Dr. Mehmet Oz, and his past stances on transgender treatments for minors and abortion, and he says the nominee hasn’t answered his inquiries. 

The Missouri Republican told Fox News Digital in an interview that he remains concerned by Oz’s past of ‘promoting transgender surgeries for minors, promoting transgender hormone treatments and puberty blockers for minors.’

He submitted a number of questions to Oz on the subjects earlier in the month, but Hawley said Oz never answered. ‘He hasn’t. Which I think is strange,’ he said. 

‘I’m hoping that he’s changed his views,’ Hawley added. ‘I’d like to hear from him that he is in total alignment with President Trump, who has been tremendously strong on this.’

In a statement to Fox News Digital, White House spokesman Kush Desai said, ‘Every member of the Trump administration is working from the same playbook, President Trump’s playbook, to restore commonsense policies and put an end to left-wing ideological nonsense afflicting our government.’

‘We look forward to the Senate’s swift confirmation of Dr. Oz so he can join the rest of our all-star team at HHS working to Make America Healthy Again by restoring common sense, transparency, and confidence in our healthcare apparatus.’

As Hawley noted, Oz has used his television show to platform people who supported and promoted transgender treatments, particularly for minors. 

Oz hosted two transgender children on his show in 2010 in a segment titled, ‘Transgender Kids: Too Young to Decide?’ 

Josie, 8, and the child’s mother, Vanessia, claimed that Josie’s life improved once the male-born child began embracing a feminine lifestyle. Isaac, who was 15, and the minor’s parents, Arturo and Monica, revealed that they decided to let their female-born teenager begin taking puberty blockers and have the teenager’s breasts removed in a double mastectomy. 

The segment was touted as ‘groundbreaking’ by LGBTQ activist group GLAAD, which told supporters to thank Oz. 

The television doctor has also had a history of supporting abortion. 

In a 2019 interview on popular radio show ‘The Breakfast Club,’ Oz said he was concerned by state laws aimed at restricting or limiting abortion, saying it’s ‘a hard issue for everybody.’

And while on ‘a personal level,’ he didn’t like abortion, he also believed he should not ‘interfere with everyone else’s stuff.’ 

‘Because it’s hard enough to get into life as it is,’ he added. 

When Oz ran for Senate in Pennsylvania as a Republican in 2022, he still opposed government jurisdiction on the subject of abortion. 

‘I don’t want the federal government involved with that at all,’ he said during a debate with now-Sen. John Fetterman, D-Pa. ‘I want women, doctors, local political leaders, letting the democracy that’s always allowed our nation to thrive, to put the best ideas forward, so states can decide for themselves.’

Asked whether he would vote to confirm Oz even without answers to his questions, Hawley wouldn’t say. ‘I just have to believe that he will respond here.’

This post appeared first on FOX NEWS

Genetic testing company 23andMe (NASDAQ:ME) has filed for Chapter 11 bankruptcy protection in a Missouri federal court, marking a dramatic fall for a company once valued at nearly US$6 billion.

Alongside the bankruptcy, the Associated Press reported that co-founder Anne Wojcicki has stepped down as chief executive, effective immediately, though she will remain on the company’s board.

Founded in 2006, 23andMe gained widespread recognition for its at-home DNA testing kits, which provided customers with insights into their genetic ancestry and health traits. The firm went public in 2021 via a merger with a special-purpose acquisition company led by billionaire Richard Branson, achieving an initial valuation of US$3.5 billion.

However, 23andMe has struggled to maintain its financial momentum in recent years, with its market capitalization dropping to less than US$20 million as of Monday’s (March 24) close.

The company has faced persistent difficulties generating recurring revenue, as many customers only purchased DNA test kits once and saw little reason to buy others.

Analysts have noted that the market for ancestry testing kits may have reached its saturation point. Meanwhile, 23andMe’s attempts to expand into research and therapeutics failed to produce sustainable revenue streams.

In March 2023, 23andMe’s independent directors formed a special committee to explore strategic options. Wojcicki submitted multiple proposals to take the company private, but all were rejected, including a bid earlier this month.

According to the company’s bankruptcy filing, 23andMe’s estimated assets and liabilities range between US$100 million and US$500 million. The firm has secured US$35 million in financing to continue operations during the bankruptcy process, with plans to sell its assets through a court-approved process.

‘We have had many successes, but I equally take accountability for the challenges we have today,” Wojcicki wrote in a post on X, formerly Twitter, early on Monday morning. “There is no doubt that the challenges faced by 23andMe through an evolving business model have been real, but my belief in the company and its future is unwavering.”

With Wojcicki’s resignation, Joseph Selsavage, the company’s chief financial and accounting officer, will serve as interim CEO. It remains unclear whether there are any interested bidders for 23andMe’s assets.

The company stated that it will continue operations while actively soliciting qualified bids over the next 45 days. Wojcicki has confirmed she intends to pursue the company as an independent bidder.

23andMe faced security concerns prior to bankruptcy

Beyond financial struggles, 23andMe has faced growing concerns about its handling of consumer data.

In October 2023, hackers accessed the personal information of nearly 7 million customers over a five month period, raising alarm among users and regulators.

California Attorney General Rob Bonta issued a consumer alert last week urging residents to consider deleting their genetic data from 23andMe’s platform due to privacy risks.

The data breach compounded the company’s existing troubles, further damaging its reputation and diminishing consumer trust. 23andMe eventually reached a US$30 million settlement in a lawsuit related to the breach late last year.

In response to concerns about how genetic data will be handled during the bankruptcy process, 23andMe has stated that there will be no changes to its data storage, management or security policies.

However, reports have highlighted that 23andMe’s privacy policies allow for the potential sale of customer data to third parties, raising further questions about how data may be managed under new ownership.

23andMe’s struggles reflect broader challenges facing the consumer DNA testing industry. Rival AncestryDNA, owned by private equity firm Blackstone (NYSE:BX), has also seen a decline in demand.

DNA test kit sales have historically spiked during the holiday season, but consumer interest has waned in recent years. The long-term viability of genetic testing companies has come into question, as privacy concerns and a lack of recurring revenue models present significant obstacles.

In response to its financial difficulties, 23andMe implemented significant cost-cutting measures, including laying off 200 employees and halting development of its therapeutics division.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Electra Battery Materials (TSXV:ELBM,NASDAQ:ELBM) announced on March 21 that it has received a letter of intent from the Canadian government for C$20 million in proposed funding.

The money would support the construction and commissioning of North America’s first battery-grade cobalt refinery, a critical step toward strengthening the region’s electric vehicle (EV) supply chain.

The refinery, located in Temiskaming Shores, Ontario, is set to produce 6,500 metric tons of cobalt sulfate annually, enabling domestic production of up to 1 million EVs per year. According to Electra, it would be a key step in reducing North America’s dependence on China, which currently refines approximately 90 percent of the world’s cobalt.

“We are grateful to be working with the Government of Canada,” said CEO Trent Mell. “Today’s announcement underscores their commitment to advancing North American energy security and critical mineral independence.”

Mell further noted that the company has already secured commitments from major buyers, with LG Energy Solution (KRX:373220) set to purchase up to 80 percent of the refinery’s future output.

“Buyer interest for the remainder far exceeds our capacity,” he added.

Anita Anand likewise emphasized the strategic importance of domestic mineral processing.

“Canada has everything it takes to be a leading force in critical minerals processing, manufacturing, and recycling. Critical minerals are essential to power a low-carbon economy,” said Canada’s minister of innovation, science and industry.

With necessary permits in place, infrastructure largely developed and advanced negotiations with the government ongoing, Electra aims to finalize discussions quickly and resume construction.

The non-binding letter of intent, which was agreed to on January 27, signals the government’s intent to work toward a final agreement, but does not yet guarantee funding. If finalized, the investment would accelerate construction and commissioning of the refinery, which is projected to have the lowest carbon footprint of any facility of its kind worldwide.

Beyond cobalt refining, Electra is exploring expansion into other battery materials.

In 2023, the company successfully operated a battery recycling demonstration plant at its Temiskaming Shores complex, recovering lithium, nickel, cobalt and other critical minerals from spent batteries.

This year, Electra commenced a feasibility study for a battery recycling refinery adjacent to its cobalt refinery. It is considering a second cobalt sulfate facility in Bécancour, Québec, as well as a North American nickel sulfate plant.

“Our Temiskaming Shores refinery complex is the first step in Electra’s vision,” noted Mell.

“We are building the right assets at the right time and are extremely well-positioned to leverage the refinery complex to grow along with the EV and battery markets,’ emphasizing the need for secure sources of battery materials.

Electra’s refinery will be one of the few cobalt suppliers outside of China that is free from Foreign Entity of Concern involvement, reinforcing supply chain resilience for North American automakers.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Brazilian Rare Earths Limited (ASX: BRE) (OTCQX: BRELY / OTCQX: BRETF) is pleased to report the results of exploration drilling at the Pelé Target 1 Project, located in Bahia, Brazil.

New discovery of high-grade REE-Nb-Sc-Ta-U mineralisation

  • High-grade diamond drill results at Pelé Target 1 returned assays of up to 13.5% TREO:
    • NdPr: 23,217 ppm | DyTb: 938 ppm | Nb2O5: 5,011 ppm | Sc2O3: 381 ppm | Ta₂O₅: 248 ppm | U3O8: 1,100 ppm
  • High-grade REE-Nb-Sc-Ta-U from shallow depths (~20 m) extending to vertical depths of ~70 m
  • Drillhole TG1DD0004 returned 29.8 m of a cumulative downhole mineralisation, including 15.3 m at 9.1% TREO from 25.6 m depth, with grades of:
    • NdPr: 15,617 ppm | DyTb: 692 ppm | Nb₂O₅: 1,861 ppm | Sc₂O₃: 231 ppm | Ta₂O₅: 94 ppm | U₃O₈: 754 ppm
  • Auger drilling continues to discover extensive, near-surface horizons of high-grade monazite sands, with grades of up to 7.9% TREO and assays of up to 11,681ppm NdPr and 580 ppm DyTb

Pelé Target 1 discoveries extend high-grade mineralised trendline to 10 km

  • Pelé is confirmed as a major district-scale rare earth exploration project located ~60 km southwest of BRE’s Monte Alto project in Bahia, Brazil, and covers an exploration area over 60 times larger than Monte Alto
  • Recent exploration has focussed primarily on Pelé Target 1 – one of five large exploration target areas within the larger Pelé Project area – delivering new discoveries of high-grade rare earth outcrops with grades of up to 17.7% TREO and high-grade monazite sands with grades of up to 8.5% TREO
  • New outcrop discoveries of high-grade REE-Nb-Sc-Ta-U mineralisation significantly extend the mineralised strike at Pelé Target 1 to over 10 km
  • Brazilian Rare Earths now controls three major confirmed projects – Monte Alto, Sulista and Pelé – each demonstrating significant diamond drill intersections of high-grade REE-Nb-Sc-Ta-U mineralisation

The Pelé Project is hosted within the Volta do Rio Plutonic Suite, a large-scale magmatic system that extends over 180 km in Bahia, Brazil. Brazilian Rare Earths has confirmed the exploration potential of the province with multiple discoveries of ultra-high-grade mineralisation, including rare earth elements (REE), niobium (Nb), scandium (Sc), tantalum (Ta), and uranium (U).

Pelé Target 1 has the largest expanse of weathered REE-Nb-Sc-U outcrops discovered since exploration commenced at the Rocha da Rocha rare earth province. New geological mapping, 75 line-km of ground gamma stations and 162 new outcrop samples highlights that REE-Nb-Sc-Ta-U mineralisation repeats along eastern and western limbs of a regional structural fold that now extends over 10 km at the project.

Successful diamond drilling at Pelé Target 1

The new drilling results are from 10 diamond core holes totalling 901 metres and 100 auger drill holes totalling 1,095 metres. Assays are pending for a further 19 auger holes totalling 243 metres.

High-grade, hard rock REE-Nb-Sc-Ta-U mineralisation was intersected from shallow depths with assay grades of up to 13.5% TREO. High grades of neodymium and praseodymium were recorded, with grades up to 23,217 ppm NdPr, as well as high grades of dysprosium and terbium of up to 938 ppm DyTb.

Click here for the full ASX Release

This post appeared first on investingnews.com

Gold’s surge to record highs is beginning to reinvigorate investor confidence in companies focused on the yellow metal, reversing months of outflows and fueling fresh optimism in the sector.

With the gold price breaching US$3,000 per ounce and climbing over 15 percent in 2025, investors are reassessing the profitability of gold-mining companies as the metal’s higher price is reflected in their results.

After a prolonged period of cost pressures from inflation-driven increases in labor and fuel costs, along with regulatory challenges, gold miners are now benefiting from improved profit margins.

According to Reuters, funds investing in gold miners are set to record their largest monthly net inflows in over a year in March. So far they have seen US$555.3 million in net inflows this month, the highest since November 2023.

Referring to LSEG Lipper data, the news outlet states that this marks a significant turnaround from 2024, when funds investing in gold stocks lost a net US$4.6 billion, the largest amount in a decade.

That’s in contrast to physical gold and gold derivatives funds, which saw net inflows of US$17.8 billion in 2024.

Investors’ increasing faith in gold stocks is being reflected in their share prices.

Newmont (TSX:NGT,NYSE:NEM) and Barrick Gold (TSX:ABX,NYSE:GOLD), which suffered losses of 10 percent and 7 percent in 2024, have surged by approximately 27 percent and 21.5 percent year-to-date.

Last month, Barrick announced a US$1 billion share buyback program after reporting solid earnings and doubling its free cashflow in the fourth quarter. Similarly, AngloGold Ashanti (NYSE:AU,JSE:ANG) recently declared its strongest balance sheet in over a decade, issuing a 2024 dividend of US$0.91 per share, nearly five times higher than the previous year.

Other gold miners, such as Gold Fields (NYSE:GFI,JSE:GFI) and Harmony Gold (NYSE:HMY,JSE:HAR), are also reportedly considering share buybacks and expansion projects.

What’s driving gold’s price rally?

One of the key catalysts behind gold’s recent surge is central bank demand.

According to the World Gold Council, central banks purchased over 1,000 metric tons of gold in 2024, the third consecutive year of significant buying and double the average annual purchase of the past decade.

Central banks in China, India, Kazakhstan, Uzbekistan and Poland have continued their aggressive gold acquisitions in 2025, driven by concerns over geopolitical risks and de-dollarization efforts.

The freezing of Russia’s US$300 billion in foreign reserves after its 2022 invasion of Ukraine is widely seen as a catalyst for central bank buying as it underscored the risks of holding assets in foreign currencies or overseas institutions.

With geopolitical uncertainties persisting and potential tariff escalations under the Trump administration, central bank demand is expected to remain strong. Investor behavior has also been influenced by economic instability, global trade tensions and expectations of US Federal Reserve rate cuts.

Statistics from the World Gold Council show that global gold exchange-traded funds saw US$9.4 billion in inflows in February, the highest monthly intake since March 2022.

How high can the gold price rise?

Gold continued to hold above US$3,010 as of Tuesday (March 25), and its resilience at the psychological US$3,000 support level suggests demand for safe-haven assets remains intact.

Instability remains high as investors speculate about US tariffs, which are set to go in effect on April 2.

Investment firm UBS (NYSE:UBS) recently raised its gold price forecast to US$3,200 over the next four quarters, citing persistent geopolitical risks and a prolonged trade conflict.

Within the gold sector, many experts have laid out much higher long-term gold price predictions.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Gibb River Diamonds Limited (ASX:GIB) has announced Edjudina Gold Project, WA – Permitting Application to Mine Neta Prospect Lodged.

  • Gibb River Diamonds Limited (‘GIB’ or the ‘Company’) is pleased to announce that a Mining Proposal covering the Edjudina Gold Project (GIB 100%) has been lodged with the West Australian Mines Department (DEMIRS)
  • The aim of the ‘Mining Proposal For Small Mining Operations’ is to permit mining of the Neta Prospect, part of the Edjudina Gold Project, which is on granted mining lease M31/495
  • The Indicated and Inferred Resource JORC resource at the Neta Prospect is 378,000 tonnes @1.9 g/t for 24,000 Oz Au and includes an Indicated Resource of 110,000 tonnes @ 2.2g/t for 8,000 Oz Au1
  • It is the primary focus of GIB to mine or otherwise monetise this Neta resource as soon as is practicable. The lodging of this Mining Proposal is an important step forward in achieving this aim
  • Once granted, the Mining Proposal will permit for a Mine and Haul operation to be conducted at the Neta Gold Prospect, using toll treatment at a third-party mill (pending commercial contracts). This is the Company’s current priority.
  • The Company is currently communicating with the WTAC Native Title group to finalise a date for a heritage survey to be conducted at the Edjudina Project. It is anticipated that this heritage survey will take place sometime in April 2025. This survey will assist in facilitating both mining at the Neta Prospect and the drilling of new exploration targets in the Company’s recently acquired and highly prospective mining lease M31/481, adjacent to the proposed Neta mining area
  • Discussions are ongoing with various West Australian groups which specialises in mine, haul and toll milling gold operations

NB: it is anticipated that subsequent to the commencent of mining, from time to time, that additional permitting will be required at Edjudina. It is not the intention of GIB to report to the ASX permitting applications, or re-submissions, which the Company does not consider to be material, but are a routine part of permitting mining operations.

About the Edjudina Gold Project

GIB’s Edjudina Gold Project is 145km north east of Kalgoorlie and is located in the heart of the Eastern Goldfields of WA. The project comprises multiple parallel lines of nearly continuous historic gold workings over a 13km strike in which high grade veins have been worked2. A haul road owned and operated by Northern Star Resources Limited runs through the north of the project directly to the Carosue Dam milling complex 45 km to the south.

Click here for the full ASX Release

This post appeared first on investingnews.com

Bitcoin is more closely correlated to the Nasdaq than it is to gold most of the time, and investors could benefit from viewing it as another big tech stock, says Standard Chartered.

Bitcoin’s correlation with the Nasdaq is currently at about 0.5, after it approached 0.8 earlier this year, according to the bank. Meanwhile, its correlation with gold has been falling since January, touching zero at one point, and is now just above 0.2.

“Bitcoin trading is highly correlated to the Nasdaq over short time horizons,” Geoff Kendrick, Standard Chartered’s global head of digital assets research, said in a note Monday. “This Nasdaq correlation leads to the idea that bitcoin could be included in a basket of large tech stocks; if it were included, the implication would be more institutional buying as BTC would serve multiple purposes in investor portfolios.”

Bitcoin is frequently viewed as “digital gold” and a hedge against risks facing the traditional financial sector. Kendrick said he still sees the flagship cryptocurrency serving that purpose but that “in reality … the need for such hedges is very infrequent.”

Standard Chartered created a hypothetical index dubbed “Mag 7B,” in which it added bitcoin to the Magnificent 7 tech stocks — Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla — and removed Tesla.

“Mag 7B has outperformed Mag 7 by about 5% over the period since December 2017,” he said. “On a calendar year basis, Mag 7B outperformed Mag 7 in five out of seven years, albeit by a very small margin in 2022. Mag 7B’s relative returns are decent on both an absolute basis (averaging around 1% a year above Mag 7) and a calendar-year basis.”

Kendrick said bitcoin has been trading in a similar volatility-adjusted fashion to Nvidia since President Trump’s inauguration. They’re down 16% and 12%, respectively, since Jan. 20. Meanwhile, Tesla, which has lost 36% in the same period, is trading more like ether (down 38% since Jan. 20).

“Investors can view bitcoin as both a hedge against [traditional finance] and as part of their tech allocation,” Kendrick said. “Indeed, as BTC’s role in global investor portfolios becomes established, we think that having more than one use will bring fresh capital inflows to the asset. This is particularly true as bitcoin investment becomes more institutionalized.”

Bitcoin is down about 5% for the year after Trump’s tariff threats in recent weeks have brought new volatility to the market. Investors are expecting relief in the second quarter, however, given bitcoin’s two of its most persistent correlations: its positive correlation with money supply growth, also known as M2, and its negative correlation with the U.S. dollar index, or DXY.

—CNBC’s Michael Bloom contributed reporting.

This post appeared first on NBC NEWS